GlassScriptPhysician profile
Kevin Ganong
NPI 1699730762
$131,358.31
in general payments reported to CMS, 2019-2025
23 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $20K · 2021: $46K · 2022: $14K · 2023: $18K · 2024: $1,965 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $1,888 · Travel and Lodging: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,450.00 |
| Food and Beverage | $1,887.88 |
| Travel and Lodging | $360.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $127,204.50 | 2019-2024 | Farxiga |
| Medtronic, INC. | $661.87 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $519.69 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $488.23 | 2022-2025 | |
| Medtronic Minimed, INC. | $450.39 | 2019-2020 | |
| Novo Nordisk INC | $427.23 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $410.88 | 2019-2025 | Mounjaro, Trulicity, Humulin |
| Amgen INC. | $319.28 | 2019-2025 | Evenity, Tepezza |
| Corcept Therapeutics | $145.62 | 2021-2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $124.92 | 2023-2024 | |
| Abbott Laboratories | $94.28 | 2025 | Freestyle Libre 3 |
| Radius Health, INC. | $85.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.50 | 2021-2023 | Jardiance |
| Sequel Med Tech, LLC | $61.57 | 2025 | Twiist |
| Beta Bionics, INC. | $56.67 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $51.06 | 2021-2023 | Senza |
| Antares Pharma, INC. | $44.20 | 2022 | |
| Dexcom, INC. | $38.51 | 2022 | |
| Merck Sharp & Dohme LLC | $28.99 | 2020-2022 | |
| Astellas Pharma US INC | $28.98 | 2023 | Veozah, Myrbetriq |
| Tandem Diabetes Care, INC. | $17.82 | 2020 | |
| Horizon Therapeutics Plc | $15.35 | 2021 | |
| Insulet Corporation | $12.94 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ganong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.